The AHA today expressed support for the Closing Loopholes for Orphan Drugs Act, H.R. 4538, bipartisan legislation that would limit the “orphan drug” exclusion for 340B Drug Pricing Program rural and cancer hospitals. Specifically, the legislation would allow 340B critical access hospitals, sole community providers, rural referral centers and free-standing cancer hospitals to purchase orphan drugs at discounted rates through the 340B program as long as the orphan drug is used to treat illnesses or conditions other than the rare illnesses or conditions for which the orphan drug designation was originally given. “In an era of ever increasing prescription drug costs, this bill is an important step to ensure 340B hospitals subject to the orphan drug exclusion can obtain lifesaving drugs at a much needed discount so they can stretch limited resources to better serve their communities,” AHA wrote in a letter of support to Reps. Peter Welch, D-V.T., and David McKinley, R-W.Va., the bill’s sponsors.

Related News Articles

Headline
Read a recap and insights from health care leaders during AHA’s July 15 webinar, “Addressing COVID-19 Vaccine Hesitancy in Your Community,” featuring messaging…
Perspective
The COVID-19 Provider Relief Fund has been a lifeline for hospitals, health systems and health care providers, allowing them to continue to put the health and…
Headline
The House today voted 219-208 to approve legislation that would provide $253.8 billion in funding for the departments of Labor, Health and Human Services, and…
Headline
The Provider Relief Fund Deadline Extension Act (S. 2493/H.R. 4735) was introduced yesterday in the Senate and House. The AHA-supported bill would allow…
Headline
Rural health clinics and other qualified community-based outpatient care centers can apply for American Rescue Plan Act funding to expand the number of full-…
Headline
The Health Resources and Services Administration yesterday awarded rural health clinics about $49,500 each for outreach to increase COVID-19 vaccinations in…